Previous 10 | Next 10 |
home / stock / evtcy / evtcy news
PARTNERSHIP COMBINES OWKIN'S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN'S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYM...
HAMBURG, GERMANY / ACCESSWIRE / January 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to...
EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY ("GHDC") AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC'S IPSC-DERIVED HIGH-T...
GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PA...
EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ("NMPA") AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC'S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD ("JINGXIN") WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA HAMBURG, GE...
PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE HAMBURG, GERMANY / ACCESSWIRE ...
CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION ALL ELEMENTS OF GUIDANCE CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / November 8, 2023 / Evotec SE (Frankf...
STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT'S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC'S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILES...
A UNIQUE COMPANY CREATION VEHICLE INITIATED BY LIGHTSTONE VENTURES AND EVOTEC SE, AND ESTABLISHED WITH PARTNERS CLAVYSTBIO, LEAPS BY BAYER, POLARIS PARTNERS, AND THE POLARIS INNOVATION FUND FIRST-OF-ITS-KIND PARTNERSHIP IN SINGAPORE AND ASIA LEVERAGES BREAKTHROUGH SCIENCE FROM RESEARCHERS AT...
LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTS AGREEMENT LEVERAGES EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND DRUG HUNTING EXPERTISE FOR LIFE SCIENCE...
News, Short Squeeze, Breakout and More Instantly...
Evotec Ag Adr Company Name:
EVTCY Stock Symbol:
OTCMKTS Market:
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC'S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D&...
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was un...
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS ...